A summary of the most common chemical descriptors (InChI Key and SMILES codes) for Acalabrutinib are summarized together with 3D and 2D structures and relevant physico-chemical properties.

What is the Acalabrutinib?

The molecule Acalabrutinib presents a molecular formula of C26H23N7O2 and its IUPAC name is 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide.

Acalabrutinib is a small molecule that inhibits Bruton's tyrosine kinase (BTK). BTK is a key regulator of B-cell activation and is essential for the development and function of B cells. Acalabrutinib is an inhibitor of BTK that blocks its activity, preventing B cells from becoming activated..

Acalabrutinib is a first-in-class, highly selective, covalent inhibitor of BTK with potent activity in vitro and in vivo. Acalabrutinib has demonstrated single-agent activity in patients with relapsed or refractory mantle cell lymphoma (MCL), and is currently being evaluated in a phase III clinical trial in patients with previously untreated MCL..

Acalabrutinib has also shown activity in patients with other B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM). In a phase I/II clinical trial in patients with relapsed or refractory CLL, acalabrutinib monotherapy resulted in an overall response rate of 79%. The most common adverse events (AEs) associated with acalabrutinib were diarrhea, fatigue, and musculoskeletal pain..

Acalabrutinib is generally well tolerated, with a favorable safety profile. The most common AEs associated with acalabrutinib are diarrhea, fatigue, and musculoskeletal pain. Acalabrutinib has also been associated with a low rate of serious AEs, including bleeding and atrial fibrillation..

Acalabrutinib is a promising new therapy for patients with B-cell malignancies. It is well tolerated and has demonstrated single-agent activity in patients with relapsed or refractory MCL, CLL, SLL, and WM..

3D structure

Cartesian coordinates

Geometry of Acalabrutinib in x, y and z coordinates (Å units) to copy/paste elsewhere. Generated with Open Babel software.

2D drawing


Acalabrutinib WDENQIQQYWYTPO-IBGZPJMESA-N chemical compound 2D structure molecule svg


Molecule descriptors

IUPAC name4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
InChI codeInChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1

Other names (synonyms)

IUPAC nomenclature provides a standardized method for naming chemical compounds. Although this system is widely used in chemistry, many chemical compounds have also other names commonly used in different contexts. These synonyms can come from a variety of sources and are used for a variety of purposes.

One common source of synonyms for chemical compounds is the common or trivial names, assigned on the basis of appearance, properties, or origin of the molecule.

Another source of synonyms are historical or obsolete names employed in the past, however replaced nowadays by more modern or standardized names.

In addition to common and historical names, chemical compounds may also have synonyms that are specific to a particular field or industry.

  • (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
  • (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide;Acalabrutinib
  • (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
  • 1420477-60-6
  • 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-Benzamide
  • 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide
  • 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
  • 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide
  • A857446
  • ACP 196
  • ACP-196
  • ACP-196;Acalabrutinib
  • AMY5290
  • Acalabrutinib
  • Acalabrutinib (ACP-196)
  • Acalabrutinib (JAN/USAN/INN)
  • Acalabrutinib(ACP196)
  • BDBM50175583
  • Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-
  • Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-
  • CCG-269407
  • CS-5356
  • Calquence
  • D10893
  • DB11703
  • DS-3326
  • EX-A881
  • GTPL8912
  • HY-17600
  • I42748ELQW
  • J-690166
  • MFCD29472294
  • NCGC00479074-01
  • NSC-791164
  • NSC-800976
  • NSC791164
  • NSC800976
  • Q23668732
  • acalabrutinibum
  • s8116

Reference codes for other databases

There exist several different chemical codes commonly used in orded to identify molecules:
  • ZINC208774715
  • UNII-I42748ELQW
  • DTXSID401026209
  • CHEMBL3707348
  • CHEBI:167707
  • SCHEMBL14637368

Physico-Chemical properties

IUPAC name4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
Molecular formulaC26H23N7O2
Molecular weight465.507
Melting point (ºC)
Boiling point (ºC)
Density (g/cm3)
Molar refractivity136.51
Topological polar surface area118.5

LogP and topological polar surface area (TPSA) values were estimated using Open Babel software.

The n-octanol/water partition coeficient (Kow) data is applied in toxicology and drug research. Kow values are used, to guess the environmental fate of persistent organic pollutants. High partition coefficients values, tend to accumulate in the fatty tissue of organisms. Molecules with a log(Kow) (or LogP) greater than 5 are considered to bioaccumulate.

TPSA values are the sum of the surface area over all polar atoms or molecules, mainly oxygen and nitrogen, also including hydrogen atoms.

In medicinal chemistry, TPSA is used to assess the ability of a drug to permeabilise cells.

For molecules to penetrate the blood-brain barrier (and act on receptors in the central nervous system), TPSA values below 90 Å2 are required. Thus, molecules with a polar surface area greater than 140 Å2 tend to be poorly permeable to cell membranes.